News
The Vacaville facility currently has a total bioreactor capacity of around 330,000 liters, making it one of the largest biologics ... offered employment by Lonza and the products currently ...
with biologics and cell and gene therapies playing larger roles in the overall mix, and Lonza has been investing heavily in new manufacturing capabilities. We sell different types of products and ...
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical ... It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health ...
Investing.com -- Lonza Group AG (SWX:LONN) today unveiled its comparative financials for its newly implemented operating model, ’One Lonza’, for the fiscal year 2024 and the first half of 2024, ahead ...
a capital project intended to enhance its ability to satisfy demand for next-generation mammalian biologics therapies. During the upgrade, Lonza will manufacture existing products for Roche at a ...
Lonza plans to invest approximately CHF 500 million to further upgrade the facility and add capabilities to meet demand for the next generation of mammalian biologics therapies. The products ...
The state’s largest pharma manufacturer – Lonza Biologics in Portsmouth – is in the process ... With their partners they are developing products that will forever change healthcare. Buildings are one ...
Wolfgang Weinand, CEO of Lonza, said the firm is excited to take the step to increase its capacity to create products in the ... the Vacaville site joins our Biologics division, we look forward ...
Lonza Earnings: Strong Demand for Biologics and Cell and Gene Therapies Should Drive Long-Term Sales
Lonza saw good momentum across its biologics, small molecules ... We sell different types of products and services to both investment professionals and individual investors.
(Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.
The Vacaville facility currently has a total bioreactor capacity of around 330,000 litres, making it one of the largest biologics manufacturing ... the facility will be offered employment by Lonza, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results